(II) Neurologic examination. (III) Biospecimens, including blood, spinal fluid, DNA, and RNA. (IV) Radiological data, including magnetic resonance imaging (MRI). (iii) Specific analytical methods for examining data. (iv) Provisions for consensus review of enrolled cases. (v) An integrated data collection network. (C) Designating a central laboratory to collect, analyze, and aggregate data with respect to research funded by the NNO Consortium and to make such data and analysis available to researchers. (3) Eligible consortia To be eligible for a grant under this section, a consortium shall demonstrate the following: (A) The consortium has the capability to enroll as research participants a minimum of 25 individuals with a diagnosis of NMO from the consortium’s designated catchment area. (B) The designated catchment area of the consortium does not overlap with the designated catchment area of another consortium already receiving a grant under this section. (4) Report Not later than 1 year after the date of the enactment of this section, and annually thereafter, the Secretary, acting through the Director of NIH, shall submit to Congress a report with respect to the NNO Consortium, to be made publicly available, including a summary of research funded by the NNO Consortium and a list of consortia receiving grants through the NNO Consortium. At the discretion of the Secretary, such report may be combined with other similar or existing reports. (5) Authorization of appropriations (A) In general There is authorized to be appropriated $25,000,000 for each of fiscal years 2018 through 2021, to remain available until expended, to carry out this section. (B) Sense of congress It is the sense of Congress that funds appropriated to carry out this section should be in addition to funds otherwise available or appropriated to carry out the activities described in this section. (b) Definitions For purposes of this section: (1) Catchment area The term catchment area means a defined area for which population data are available. (2)